Drug intelligence / Profile preview

BWC5167

Development stage: Preclinical
Lead developer: Bugworks Research
Modality: Small Molecules

Overview

BWC5167 is a preclinical-stage small molecule modulator of the spliceosome, currently under development by Bugworks Research. The drug is primarily being investigated for the treatment of pancreatic cancer. By targeting the spliceosome—a complex molecular machine responsible for removing introns from pre-mRNA—BWC5167 aims to disrupt the aberrant splicing patterns often found in cancer cells, which can lead to tumor cell death or growth inhibition. It is currently in the lead generation phase of preclinical development.

Targets

spliceosome (NineTeen Complex)

Beyond the preview

Go deeper on BWC5167.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWC5167.

Explore the full profile